Commenting on the campaign, Shivam Puri, MD & CEO, Cipla Health Ltd. said, "Cipladine has long been a trusted name in first aid, making it India's No. 1 antiseptic ointment. With our new 'Fast Aid' ...

Cipla Ltd reported a robust 30% YoY increase in consolidated net profit, reaching Rs 1,222 crore for Q4 FY25, driven by strong sales in India, the US, and Africa. For the full fiscal year, net ...

Cipla, India's third-biggest drugmaker by sales, reported a fourth-quarter profit that beat estimates on Tuesday (May 13, 2025), helped by strong demand for its drugs used to treat chronic ...

Under this agreement, Cipla has exclusive rights to market the innovative treatment for post-operative inflammation and pain following ocular surgery across 11 countries such as India, South ...

Taiwan-based Formosa Pharmaceuticals (6838.TW) today announced an exclusive licensing agreement with Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referred to as "Cipla" for the commercialization of ...

Drugmaker Cipla has got regulatory approval to market Afrezza, a rapid acting insulin delivered through an inhaler, as compared to other insulins given through injections. The Central Drugs ...

Cipla share price: Cipla Ltd shares fell the most in terms of percentage among all the 50 companies in the NSE Nifty today on Wednesday, October 30, 2024. Cipla share price: Cipla Ltd shares fell ...

Cipla reported a consolidated net profit of 13.03 billion rupees ($155 million) for the quarter ended Sept. 30, beating analysts' estimate of 12.34 billion rupees, as per data compiled by LSEG.

The stock came under selling pressure as the FDA continued a week-long surprise audit at one of the company’s key facilities, according to a CNBC-TV18 report last week. Shares of Granules India ...

Cipla management outlines new focus areas for the future Promoter stake sale this year was towards social efforts, management tells shareholders By Our Bureau ...